Wednesday, Jun 29, 2022
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Panacea Biotec Files Suit Against Sanofi For Patent Infringement
Ads

Panacea Biotec files suit against Sanofi for patent infringement

By PTI
Published: Published Date - 09:00 PM, Mon - 17 May 21
The EasySix vaccine comes in a pre-filled syringe and is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza Type B and Inactivated Polio. The EasySix vaccine comes in a pre-filled syringe and is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza Type B and Inactivated Polio.

New Delhi: Panacea Biotec on Monday said it has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine.

The firm said a case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix.

“The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine by the Drugs Controller General (India),” Panacea Biotec said in a regulatory filing.

On May 11, 2021, when the suit was listed before the Delhi High Court, after elaborate submissions from both parties, Sanofi undertook that it could not manufacture or market any product which infringes the amended claims of Panacea patent, it added.

Panacea said Sanofi has been contesting the patent before the Indian Patent Office since 2017, where the dispute has spilled before the Bombay and Delhi High Courts in 2018 and 2019, respectively.

The EasySix vaccine comes in a pre-filled syringe and is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza Type B and Inactivated Polio.

EasySix has been in the market since 2017 and the company expects it to be a part of government vaccination, immunisation programmes, both domestically and internationally, Panacea Biotec noted.

Panacea Biotec shares were trading 1.63 per cent down at Rs 374.30 apiece on the BSE.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • EasySix
  • EasySix vaccine
  • hexavalent vaccine
  • Panacea Biotec

Related News

  • Nokia sues OPPO over patent infringement, brand hits back

  • RDIF, Panacea Biotec launch production of Sputnik V vaccine in India

  • Adar Poonawalla exits Panacea Biotec

Latest News

  • Special drive in UP to provide crop insurance to farmers

    17 mins ago
  • Gold seized at RGIA in Hyderabad

    20 mins ago
  • School shootings in US rise to highest number in 20 years: Report

    1 hour ago
  • Tesla lays off 200 Autopilot employees in latest jobs cut: Report

    1 hour ago
  • Udaipur horror: Muslim organisations condemn tailor’s killing

    58 mins ago
  • Why speed dating is relevant in today’s time

    2 hours ago
  • G7 commits to boost India’s clean energy transition

    2 hours ago
  • Centre approves Rs 3,760 crore works for 34 national highways in Gujarat

    2 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam